The evaluation of the topical effect of Chamomile Oil on improving neuropathy symptoms in controlleddiabetic patients attend Shiraz diabetes clinic in 2022 A randomized double-blinded controlled clinical trial

开始日期2024-08-05

申办/合作机构

Shiraz University of Medical Sciences

IRCT20150531022498N11 / Completed临床2/3期IIT

Effects of concurrent training combine with Chamomile consumption on glucose homeostasis, anxiety, depression, general health, body composition and physical fitness in overweight and obese women

开始日期2017-09-22

申办/合作机构

Islamic Azad University

NCT01072344 / Completed临床3期IIT

Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD)

Prior research has shown that chamomile may be an effective, short-term anti-anxiety treatment. This study will examine the initial and long-term benefits of chamomile extract therapy for the prevention of recurrent anxiety disorder.

开始日期2010-02-01

申办/合作机构

University of Pennsylvania

100 项与洋甘菊提取物相关的临床结果

登录后查看更多信息

100 项与洋甘菊提取物相关的转化医学

登录后查看更多信息

100 项与洋甘菊提取物相关的专利（医药）

登录后查看更多信息

215

项与洋甘菊提取物相关的文献（医药）

2024-10-01·RADIOTHERAPY AND ONCOLOGY

Comparison of liposomal gel with and without addition of chamomile for prevention of radiation dermatitis in head and neck cancer patients: A randomized controlled trial

Article

作者: Menêses, Amanda Gomes ; Ciol, Marcia A ; Guerra, Eliete Neves Silva ; Reis, Paula Elaine Diniz ; Vieira, Larissa Aparecida Corrêa ; Bontempo, Priscila de Souza Maggi ; Ferreira, Elaine Barros

BACKGROUND AND PURPOSE:

Head and neck cancer patients frequently develop radiation dermatitis (RD) during radiotherapy. We compared liposomal gel with and without chamomile extract for the prevention and management of RD in head and neck cancer patients undergoing radiotherapy.

MATERIALS AND METHODS:

Sixty participants undergoing radiotherapy for the first time for head and neck cancer were recruited in a double-blind randomized clinical trial. Primary outcomes were the occurrence of dry desquamation and the cumulative dose of ionizing radiation at the first occurrence of dry desquamation. Secondary outcomes were the occurrence of erythema, moist desquamation, global RD, and participant self-reported symptoms.

RESULTS:

Dry desquamation occurred in 76.9 % (95 % CI: 57.9, 89.0) of participants in the chamomile liposomal gel group and in 88.9 % (95 % CI: 71.9, 96.1) in the liposomal gel group (p = 0.43). The median cumulative dose of ionizing radiation when dry desquamation occurred was 48.0 Gy in the chamomile liposomal gel group and 40.0 Gy in the liposomal gel group. Fewer symptoms were reported in the chamomile liposomal gel group.

CONCLUSION:

No statistically significant differences in outcomes were found between the two groups, though the chamomile liposomal gel group presented with lower grades of RD than the liposomal gel group. In addition, when compared to the literature on other topical interventions to manage RD, our results show that chamomile liposomal gel has potential for better management and prevention of RD in this population, which should be further tested. This study provides crucial information to design future studies. Clinical Trials Registration (REBEC): RBR-92cts3.

2024-10-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Therapeutic effects of chamomile volatile oil nanoemulsion/Bletilla striata polysaccharides gels on atopic dermatitis

Article

作者: Chen, Gang ; Zhang, Dacun ; Xu, Jian ; Hu, Hanlu ; Chen, Bin ; Zhou, Qian ; Chen, Guoqing ; Ma, Shihong ; Qian, Xue ; Zhang, Fenglun ; Huang, Xiaode

Atopic dermatitis (AD) is a prevalent chronic skin condition characterized by complex immune responses. Chamomile possesses potent anti-inflammatory properties and has been widely used in treating various skin diseases. This study aimed to assess the therapeutic benefits of chamomile volatile oil nanoemulsion gels (CVO-NEGs) for the treatment of AD. Chamomile volatile oil nanoemulsions (CVO-NEs) were prepared using the phase transition method, yielding spherical nanoparticles with a particle size of 19.07 nm. Subsequently, Bletilla striata polysaccharides were employed to encapsulate CVO-NEs, resulting in the formation of CVO-NEGs. In vivo studies demonstrated that the preparation of CVO-NEGs enhanced the biological activity of volatile oil in AD therapy. Histopathological results indicated that CVO-NEGs reduced skin damage, epidermal thickness, and mast cell infiltration. CVO-NEGs suppressed IgG production and reduced the levels of cytokines, including TNF-α, IL-4, and IFN-γ, in AD mice. Furthermore, flow cytometry revealed that CVO-NEGs were involved in regulating the differentiation of CD4⁺ T cell subsets. The immune imbalance of Th1/Th2 in AD mice can be controlled, resulting in a reduction in the hypersensitivity reaction caused by excessive Th2 activation. In conclusion, the present study confirms that CVO-NEGs have the potential to serve as an effective alternative treatment for AD.

2024-09-12·STRAHLENTHERAPIE UND ONKOLOGIE

Comparison of liposomal gel with and without chamomile to prevent radiation dermatitis in breast cancer patients: a randomized controlled trial.

Article

作者: Ciol, Marcia Aparecida ; Guerra, Eliete Neves Silva ; Reis, Paula Elaine Diniz Dos ; Meneses, Amanda Gomes de ; Vieira, Larissa Aparecida Corrêa ; Bontempo, Priscila de Souza Maggi ; Ferreira, Elaine Barros

PURPOSE:

To compare a liposomal gel with and without chamomile extract for the prevention of radiation dermatitis in breast cancer patients undergoing radiotherapy.

METHODS:

This study was a double-blind randomized clinical trial. A total of 100 participants undergoing radiotherapy for breast cancer were recruited. The primary outcome was the occurrence of dry desquamation. Cumulative dose of ionizing radiation at the first occurrence of dry desquamation, occurrence of erythema, moist desquamation, global radiation dermatitis, and any signs and symptoms self-reported by participants were secondary outcomes.

RESULTS:

Dry desquamation occurred in 6.0% of the participants using chamomile liposomal gel and 12.2% of those using liposomal gel (p = 0.32). The mean cumulative dose of ionizing radiation for the first occurrence of dry desquamation was 45.1 Gy in the chamomile liposomal gel group and 43.7 Gy in the liposomal gel group. There were no differences between the two gels in the occurrence of erythema, dry desquamation, moist desquamation, and radiation dermatitis compared to liposomal gel. There was a lower proportion of reported symptoms in the chamomile liposomal gel group compared to liposomal gel group in the first 3 weeks of radiation, especially for itching (p = 0.05).

CONCLUSION:

No statistically significant differences between the two gels were found in radiation dermatitis occurrence and dose at first occurrence. Comparing to the literature, it seems that both interventions may be effective, which might explain the lack of statistical difference between the groups.

项与洋甘菊提取物相关的新闻（医药）

2024-03-28

·PRNewswire

Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children with the Introduction of bébé Bottoms™ Diaper Rash Crème Spray

Made with TLC – Thin Layer Care ™ Technology, New bébé Bottoms ™ Diaper Rash Crème Spray Combines Zinc Oxide (10%) with Soothing Chamomile and Calendula in a Convenient, No-Touch Spray Application HAWTHORNE, N.Y., March 28, 2024 /PRNewswire/ -- While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed. The light spray, which is formulated with 10% zinc oxide, organic chamomile and calendula, effortlessly covers the affected area, creating a protective barrier that helps soothe baby's diaper rash while allowing skin to breath and heal. It's gentle enough to use at each diaper change to help prevent future irritation. "Taro looks to bring forth novel delivery formats and formulas, which is why we are excited about bébé Bottoms unique TLC - Thin Layer Care ™ spray technology, so parents can easily and effectively protect their baby's delicate skin from diaper rash without the need for a messy traditional cream." says Nivaran Kapur, Head of OTC business at Taro. "This is the second brand for children in the Taro branded OTC portfolio, which also includes FeverAll®, a doctor-recommended acetaminophen suppository product for fever and pain in children as young as 6 months of age." Though gentle, new bébé Bottoms is made with 10% zinc oxide, which is dermatologically tested in its efficacy for both preventing and treating diaper rash. The reduced zinc oxide concentration means it can have a thinner consistency that sprays easily and absorbs quickly. In addition, bébé Bottoms is formulated with organic chamomile and calendula, which combine to help soothe and moisturize the skin to support the skin's natural self-healing ability. The bébé Bottoms formulation has undergone multiple dermatological tests to ensure safety and effectiveness. It is free of harsh chemicals, parabens, dyes, and fragrances, making it suitable for delicate, irritated skin. "It acts like a light lotion to hydrate the skin and helps repair the skin for up to 24 hours with each application. When using it at every diaper change, the crème keeps moisture away from irritated skin so it can heal and prevent further irritation, while the convenient spray technology means you do not need to rub the product in, which can further irritate already painful skin," adds Kapur. New bébé Bottoms Diaper Rash Crème Spray is available to purchase on Amazon and will expand to other major retailers in the coming months. To learn more, visit . About Taro Pharmaceuticals U.S.A., Inc. Taro Pharmaceuticals U.S.A., Inc. was founded in 1988 and is based in Hawthorne, New York. Taro Pharmaceuticals U.S.A., Inc. operates as a subsidiary of Taro Pharmaceutical Industries Ltd. Taro is a research-based international pharmaceutical company that was established on the principal that research and development would be the cornerstone of its growth strategy. Providing quality products through scientific innovations, diligence and precision is the goal of all of Taro's research programs. Taro develops high-quality, proprietary, and off-patent pharmaceuticals for markets in the U.S., Canada, Israel and other countries around the world. The Company produces a wide range of prescription and over-the counter products including bébé Bottoms ™, FeverAll® Acetaminophen Suppositories, FeverAll® Liquid Oral Acetaminophen, tablets, capsules, suspensions, solutions, creams, and ointments. SOURCE Taro Pharmaceuticals U.S.A., Inc.

2024-03-26

·PRNewswire

CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews

Pet Hip and Joint Health Chews and Pet Calming Care Chews improve the physical and emotional well-being of dogs SAN DIEGO, March 26, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, proudly announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the industry-leading +PlusCBD lineup are now available nationwide at select retailers and from our website at . Continue Reading Pet Chews Available Now! The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBD™Pet has developed a premium CBD chew with the mission of providing the highest quality ingredients and best-in-class health and nutrition for cherished family members - our pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, our chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of your loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in your devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, our chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions. Joseph Dowling, CEO of CV Sciences, commented on the significance of the NASC safety study, stating, "The NASC's comprehensive safety study further validates CBD supplements to promote the health and wellness of our family pets. Our long-standing commitment to quality and safety will provide pet owners with products they can trust. We are immensely proud to offer CBD chews that not only meet our rigorous standards, but also exceed industry benchmarks for safety and efficacy." +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of our human consumers, including +PlusCBD™ Reserve Collection Extra Gummies, +PlusCBD™ Reserve Collection Sleep Gummies, +PlusCBD™ Daily Balance THC-Free Gummies and Softgels and +PlusCBD™ Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives. For more information, please visit +PlusCBD or CV Sciences. About CV Sciences, Inc. CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company's Cultured Foods™ brand provides a variety of 100% plant-based food products. Committed to crafting nutritious and flavorful alternatives, Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. CV Sciences, Inc. has primary offices and facilities in San Diego, California, and Warsaw, Poland. The Company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics. Additional information is available from OTCMarkets.com or by visiting . Media Contact: Alexis Isaacs [email protected] SOURCE CV Sciences, Inc.

2023-06-12

·GlobeNewswire-Health Care

SOMAÍ Pharmaceuticals Signs Supply Contract with Cosma Poland

LISBON, Portugal, June 12, 2023 (GLOBE NEWSWIRE) -- SOMAÍ Pharmaceuticals Unipessoal LDA (“SOMAÍ”) has entered into a two-year supply agreement with a well-respected Polish distributor Cosma Cannabis. Cosma produces medical-grade cannabis products for importation and distribution across Poland. The contract represents 1,000,000 euros in sales for SOMAÍ's 2024 goals to develop the fast-emerging medical cannabis markets of Poland. “We are very proud that Cosma has chosen SOMAÍ Pharmaceuticals as their preferred manufacturer to penetrate the Polish market with our extract formulations,” said SOMAÍ Pharmaceuticals CEO and Chairman Michael Sassano. “Being one of the first manufacturers in a large market with positive regulatory reforms must have good partners like Cosma that can effectively educate and represent our current and future product offerings.” By the terms of the agreement, SOMAÍ has agreed to supply medical cannabis products to Cosma for distribution in Poland under the trademark of Cosma. Additionally, Cosma will be granted Marketing Authorization to supply, market, and distribute the products within the designated territory. It has been stipulated in the agreement that Cosma will carry out the distribution of the products in compliance with the agreed-upon terms and conditions. The medical cannabis products distributed under the Agreement consist of oil drops in various ratios of THC/CBD, including 25:1, 10:10, 2.5:25, and 20:1. The Polish market for medical cannabis products has grown rapidly in recent years, with a number of patients seeking alternative treatments for conditions such as chronic pain, multiple sclerosis, and epilepsy. The demand for high-quality medical cannabis products in Poland is exceptionally high. SOMAÍ Pharmaceuticals' products are especially needed in the Polish market due to their high quality and effectiveness in treating various medical conditions, such as chronic pain, multiple sclerosis, chemotherapy-induced nausea and vomiting, and epilepsy. “Initiation cooperation with SOMAÍ has allowed us to offer innovative medicinal substances in the Polish market. We plan to develop products dedicated to Eastern Europe patients jointly. Due to the unique composition and the use of particular ingredients in these products, their absorption by the human body will be much greater than that of competitor’s products.” – said Lukasz Kreski, CHAIRMAN and Co-Founder of COSMA. “We also plan to begin joint clinical research and studies in pain management, inflammatory conditions, neurodegenerative diseases, and oncology.” About SOMAÍ Pharmaceuticals Ltd. SOMAÍ Pharmaceuticals is an international company focused on the extraction of the cannabis plant and manufacturing pharmaceutic formulations for the EU market. The company invests in the extraction, research, development, and distribution of EU GMP-pharmaceutical market-authorized cannabinoid products. For more information, please visit SOMAÍ’s website. You can read SOMAÍ’s and CEO Michael Sassano’s articles here. Press Contacts:Nataliia GarninaMarketing Manager+351 963 551 216ng@somaipharma.eu Commercial Contact:Geroge BellowChief Operational OfficerGeorge@somaipharma.eu ABOUT COSMA Cosma Cannabis is a Polish cannabis company. Cosma offers natural and safe dietary supplements that are based solely on high-quality, natural herbal extracts and free of synthetic additives. By incorporating traditional herbal extracts such as chamomile, mint, and hops, Cosma's products cater to the specific needs of patients. The key advantages of Cosma products include proven and consistent composition, easy dosing, and the absence of psychoactive tetrahydrocannabinol. For more information, please visit https://cosmacannabis.com/. Commercial Contact:Lukasz KreskiChairman/Co-Founderlukasz.kreski@cosma.pl

引进/卖出

100 项与洋甘菊提取物相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
焦虑症	临床3期	美国	University of Pennsylvania	2010-02-01
广泛性焦虑障碍	临床3期	美国	University of Pennsylvania	2010-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Oral Dis	N/A	化疗性口腔黏膜炎	45	topical chamomile (Conventional symptomatic treatment)	觸餘願製獵夢蓋顧顧鑰(鬱鑰窪繭鹹鹹醖範繭積) = 選積窪遞廠餘鹽鹽糧選選製壓繭簾膚廠構獵顧 (築窪鑰膚簾襯夢願製壓 )	积极	2022-01-01
				3% chamomile topical oral gel	觸餘願製獵夢蓋顧顧鑰(鬱鑰窪繭鹹鹹醖範繭積) = 齋積廠築構蓋範艱鬱製選製壓繭簾膚廠構獵顧 (築窪鑰膚簾襯夢願製壓 )
NCT01072344 (CTgov)	临床3期	焦虑症 \| 广泛性焦虑障碍	180	Chamomile (Matricaria recutita) (Chamomile Extract)	選觸製膚膚願襯憲鏇餘(憲獵簾壓鬱淵淵網膚築) = 艱窪顧醖願糧廠鏇窪糧廠醖網蓋膚網遞築壓製 (壓遞艱衊鏇鹽壓窪選鏇, 選遞鑰衊鹽鹽繭築網餘 ~ 繭範壓鬱構糧齋艱憲選) 更多	-	2017-07-06
				Chamomile (Matricaria recutita) (Placebo)	選觸製膚膚願襯憲鏇餘(憲獵簾壓鬱淵淵網膚築) = 網鹹繭鬱簾網顧衊廠憲廠醖網蓋膚網遞築壓製 (壓遞艱衊鏇鹽壓窪選鏇, 範製窪鏇艱壓鑰範積膚 ~ 衊淵齋醖繭觸築積鹹蓋) 更多
NCT01072344 (Pubmed \| Pharmacopsychiatry)	临床3期	广泛性焦虑障碍	179	Chamomile pharmaceutical grade extract 1500mg	衊選淵膚夢壓築簾襯鹽(鑰網繭夢範鹽構淵鑰鹽) = 鏇淵築觸夢獵觸齋鏇廠願憲範製遞衊網餘夢網 (顧餘淵齋壓製觸襯範範, ± 8.4)	-	2016-12-15
				Placebo	衊選淵膚夢壓築簾襯鹽(鑰網繭夢範鹽構淵鑰鹽) = 鹹鏇鏇簾衊壓鹹網艱積願憲範製遞衊網餘夢網 (顧餘淵齋壓製觸襯範範, ± 3.9)